Investment Rating - The investment rating for the company is "Buy" and the rating has been maintained [4][11]. Core Insights - The company has shown significant growth with a revenue of 2.375 billion yuan in 2025, marking a year-on-year increase of 135.27%. The net profit reached 644 million yuan, a substantial increase from the previous year, indicating the first annual profit for the company [3][11]. - The revenue structure is shifting from a single product focus to a dual-driven model of commercial sales and technology licensing, with drug sales contributing approximately 60.73% and technology licensing accounting for about 38.07% of total revenue [3][11]. - The core product, Acalabrutinib, continues to see rapid commercialization, achieving sales of 1.41 billion yuan, a year-on-year growth of 40.99%. The product's inclusion in medical insurance has significantly improved patient accessibility [3][6][11]. Financial Performance - In 2025, the company reported a net cash flow from operating activities of 84 million yuan, and R&D expenses were 952 million yuan, reflecting a year-on-year increase of 16.82% [3][11]. - The company expects revenues of 2.106 billion yuan, 2.633 billion yuan, and 3.258 billion yuan for 2026, 2027, and 2028 respectively, with a projected net profit of -0.85 million yuan, 116.56 million yuan, and 377.17 million yuan for the same years [11][13]. Product Development - The company has initiated commercialization of Tafasitamab and received NMPA approval for Zolbetuximab, expanding its product matrix and opening new revenue streams [6][10]. - The BCL-2 inhibitor Mesutoclax is progressing through clinical trials and is expected to become a strategic pillar in the hematology sector, with multiple key trials underway [7][11]. - The company is also deepening its layout in the autoimmune disease field, with ongoing clinical developments for Acalabrutinib and TYK2 products across various indications [8][9]. Market Position and Future Outlook - The company is enhancing its commercialization capabilities, which is expected to support revenue growth in the hematology sector and strengthen its long-term global value [6][11]. - The ADC platform is showing significant progress, with multiple candidates in clinical development, providing a continuous growth engine for the company [10][11].

Core Viewpoint - The company reported a revenue of 950 million yuan for H1 2025, with a net loss of 145 million yuan, indicating a challenging financial period despite the commercial launch of key products [1] Business Analysis - The company is in its commercialization year, with sales beginning to ramp up. It has three products approved for market: Jiatailai (TROP2 ADC), Ketailai (PD-L1 monoclonal antibody), and Datailai (rituximab), covering 30 provinces and over 2,000 hospitals [1] - Jiatailai has received approval for two key indications: 2L+TNBC (triple-negative breast cancer) and 3L EGFRmt NSCLC (non-small cell lung cancer), with additional indications in the NDA stage and ongoing clinical trials, indicating a significant market opportunity [1] Future Clinical Pipeline - The company has a robust clinical pipeline with several products in various stages: A166 (HER2 ADC) in NDA stage, A400 (RET inhibitor) in registration clinical stage, and SKB315 (CLDN18.2 ADC) exploring combinations with PD-L1 monoclonal antibodies [2] - The ongoing clinical trials for SKB571 (EGFR/c-Met ADC) and SKB378 (TSLP) further enhance the company's long-term growth prospects [2] Profit Forecast and Valuation - The company expects revenues of 2.325 billion yuan, 3.668 billion yuan, and 5.352 billion yuan for 2025, 2026, and 2027 respectively, with a projected net profit of -350 million yuan, -51 million yuan, and 380 million yuan for the same years [2]

Core Viewpoint - Nanwei Technology is positioned as a leading company in high-performance nano microsphere materials, with significant improvements in performance margins and growth opportunities in the chromatography filler sector due to import substitution and commercialization expansion [2][3][6]. Company Overview - Established in 2007, Nanwei Technology specializes in the R&D, mass production, sales, and application services of high-performance nano microsphere materials for various sectors including biomedicine and diagnostics [2]. - The company faced growth pressures in 2023 due to external macroeconomic changes, but has shown significant performance recovery since Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [2]. Market Opportunities - The global chromatography media market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. The Chinese market is expected to grow from 11.2 billion yuan to 20.3 billion yuan in the same period, with a CAGR of 21.92% [3]. - Nanwei Technology is well-positioned to benefit from two major opportunities: import substitution and commercialization expansion. The company has developed a comprehensive range of chromatography fillers and media, making it a key player in the domestic market [3][4]. Import Substitution Opportunity - The chromatography filler and media industry has been historically dominated by foreign companies, with low domestic production rates. The rapid development of the domestic biomedicine industry and geopolitical tensions are driving the need for local alternatives [3]. - Successful project changes by downstream client Heng Rui Pharmaceutical provide a template for future import substitution projects, positioning Nanwei Technology as a leader in this transition [3]. Commercialization Expansion Opportunity - The usage of chromatography fillers and media increases with project phases, from early clinical trials to commercialization. Nanwei Technology has accumulated a growing number of clients and is nurturing numerous mid-to-late clinical projects, which are expected to yield significant returns [4]. Industry Chain Layout - Beyond its core business, Nanwei Technology is expanding its industry chain through a combination of self-built and acquired entities, including subsidiaries focused on chromatography instruments and diagnostic materials [5]. - Key subsidiaries include: - Fuli Instruments, a leader in domestic chromatography instruments, has made strides in gas and liquid chromatography [5]. - NAP Analysis, which focuses on high-quality laboratory chromatography consumables, achieving full domestic production [5]. - Saip Instrument, which develops precision purification equipment for large biomolecules, establishing itself as a leader in the domestic market [5]. Financial Forecast - Revenue projections for Nanwei Technology are 1 billion yuan in 2025, 1.24 billion yuan in 2026, and 1.55 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan [6]. - The company is expected to maintain a strong growth trajectory, supported by its leadership in the chromatography filler and media sector and its strategic industry chain expansions [6].

Investment Rating - The investment rating for the company is "Buy" [2]. Core Insights - The company, Nanwei Technology, is a leader in high-performance nano-microsphere materials, with significant improvements in performance margins. The company has faced growth pressures due to external macroeconomic changes since 2023, but has shown notable recovery starting from Q4 2024, with a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [4][33]. - The company is positioned to capitalize on two major opportunities in its chromatography filler business: import substitution and commercialization expansion. The global chromatography medium market is projected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. In China, the market is expected to grow from 11.2 billion yuan in 2023 to 20.3 billion yuan by 2026, with a CAGR of 21.92% [5][18]. - The company is expanding its industrial chain through a dual approach of self-building and acquisitions, enhancing its business extensibility and opening up growth ceilings [7][20]. Summary by Sections Company Overview - Nanwei Technology, established in 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving various sectors including biomedicine, flat panel displays, analytical testing, and in vitro diagnostics. The company aims to become a global leader in microsphere brands [21][23]. Chromatography Filler Business - The chromatography filler and chromatography medium are critical consumables for biopharmaceutical separation and purification. The company has developed a comprehensive range of products, making it a key player in the domestic market. The company is expected to benefit from import substitution and commercialization opportunities, with successful case studies already established [5][18]. Industrial Chain Layout - The company is actively building its industrial chain by acquiring and establishing subsidiaries focused on chromatography instruments, consumables, and purification systems. This strategy is expected to enhance its market position and operational efficiency [7][20]. Financial Forecast and Investment Rating - Revenue projections for the company are 1.001 billion yuan in 2025, 1.244 billion yuan in 2026, and 1.549 billion yuan in 2027, with corresponding net profits of 141 million yuan, 221 million yuan, and 285 million yuan. The company is rated positively due to its leading position in the chromatography filler and medium industry, along with favorable market conditions [8][10].

Investment Rating - The investment rating for the company is "Buy" [2]. Core Insights - The company, Nanwei Technology, is a leader in high-performance nano-microsphere materials, with significant improvements in its performance margins. The company has faced growth pressures due to external macroeconomic changes since 2023, but has shown notable recovery since Q4 2024, achieving a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [4][33]. - The company is positioned to capitalize on two major opportunities in its chromatography filler business: import substitution and commercialization expansion. The global chromatography medium market is expected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. In China, the market is projected to grow from 11.2 billion yuan in 2023 to 20.3 billion yuan by 2026, with a CAGR of 21.92% [5][18]. - The company has established a comprehensive layout in the upstream and downstream of the industry chain, enhancing its growth potential. Through a combination of self-built and acquired subsidiaries, it has expanded into chromatography instruments, consumables, protein purification systems, and in vitro diagnostic consumables [7][20]. Summary by Sections Company Overview - Nanwei Technology, founded in 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving various sectors including biomedicine, flat panel displays, analytical testing, and in vitro diagnostics. The company aims to become a global leader in microsphere technology [4][21]. Chromatography Filler Business - The chromatography filler and chromatography medium are critical consumables for biopharmaceutical separation and purification. The company is well-positioned to benefit from the ongoing import substitution and commercialization expansion in this sector [5][18]. - The company has developed a full range of chromatography fillers and media, making it a key player in the domestic market, which has historically been dominated by foreign brands [5][18]. Financial Projections - Revenue projections for the company from 2025 to 2027 are 1.00 billion yuan, 1.24 billion yuan, and 1.55 billion yuan, respectively. Corresponding net profits are expected to be 141 million yuan, 221 million yuan, and 285 million yuan, with earnings per share (EPS) of 0.35 yuan, 0.55 yuan, and 0.71 yuan [8][10]. Subsidiary Overview - The company has several key subsidiaries, including: 1. Fuli Instruments, a leading domestic chromatography instrument manufacturer [11]. 2. NAP Analysis, focusing on high-quality laboratory chromatography consumables [11]. 3. Saip Instrument, specializing in precision purification equipment for biopharmaceuticals [11][20]. Market Opportunities - The company is expected to benefit from the increasing domestic demand for chromatography fillers and media, driven by the growth of the biopharmaceutical industry and the trend towards import substitution [5][18].